Table 2.
Patient characteristics and inflammation markers in relation to allergen component sensitization (n = 408)
| Peanut and Hazelnut in any combination PH:1 PH:2 PH:3 |
Peanut P:1 P:2 P:3 |
Hazelnut H:1 H:2 H:3 |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Number (%) | 179 (44) | 156 (38) | 73 (18) | 207 (51) | 141 (34) | 60 (15) | 188 (46) | 179 (44) | 41 (10) |
| Age (years)a | 20.9 ± 0.5 | 21.2 ± 0.6 | 17.6 ± 0.7*,# | 21 ± 0.5 | 21 ± 0.6 | 17.2 ± 0.7¤,# | 20.8 ± 0.5 | 20.5 ± 0.5 | 17.9 ± 0.9 |
| Femaleb | 95 (53) | 83 (53) | 30 (41) | 107 (52) | 77 (55) | 24 (40) | 101 (54) | 90 (50) | 17 (41) |
| FeNO (ppb)3 | 12.7 (11.3–14.2) | 16.7 (14.8–18.7)* | 23.2 (19.6–27.5)*,# | 13.1 (11.7–14.5) | 17.3 (15.4–19.5)¤ | 23.6 (19.5–28.5)¤,# | 12.8 (11.5–14.3) | 17.7 (15.8–19.9)∆ | 23.5 (19.1–29)∆ |
| FEV1 (%)1 | 92.9 ± 1.1 | 92.2 ± 1.2 | 89.6 ± 1.6 | 93 ± 1 | 91.8 ± 1.2 | 89.4 ± 1.8 | 92.9 ± 1 | 91.9 ± 1 | 89 ± 2.4 |
| Methacholine ch.test (PD20)d | 0.4 (0.1–3) | 0.3 (0.1–1.8) | 0.1 (0.1–0.4)* | 0.4 (0.1–2.9) | 0.3 (0.1–1.2) | 0.1 (0–0.1) | 0.4 (0.1–7.2) | 0.3 (0.1–1.2) | 0.1 (0–0.6) |
| Eosinophils (109/L)c | 0.15 (0.13–0.16) | 0.17 (0.15–0.2) | 0.34 (0.29–0.41)*,# | 0.14 (0.13–0.16) | 0.19 (0.17–0.22)¤ | 0.34 (0.28–0.41)¤,# | 0.15 (0.13–0.17) | 0.19 (0.17–0.22)∆ | 0.37 (0.29–0.46)∆,☼ |
| ECP (µg/L)c | 11.6 (10.5–12.7) | 12.4 (11.1–13.8) | 20 (17–23.5)*,# | 11.6 (10.6–12.7) | 13.2 (11.7 –14.9) | 19.7 (16.5–23.5)¤,# | 11.7 (10.6–12.8) | 13.1 (11.8–14.5) | 22.1 (17.8–27.4)∆,☼ |
| Total IgE (kU/L)c | 58 (46–73) | 213 (176–258)* | 523 (396–689)*,# | 63 (51–78) | 265 (216–325)¤ | 515 (378–701)¤,# | 62 (49–77) | 226 (190–270)∆ | 803 (557–1158)∆,☼ |
| Eczema (ever)b | 67 (37) | 100 (64)* | 59 (81)*,# | 77 (37) | 101 (72)¤ | 48 (80)¤ | 73 (39) | 118 (66)∆ | 35 (85)∆,☼ |
| Inh.corticosteroids (µg/day)c | 404 (369–443) | 416 (375–461) | 358 (315–407) | 400 (369–434) | 425 (380–475) | 345 (299–399) | 404 (370–442) | 404 (367–444) | 368 (307–442) |
| Birch pollen sensitizationb | 13 (7) | 151 (97) * | 64 (88)*,# | 39 (19) | 137 (97) ¤ | 52 (87)¤,# | 14 (7) | 176 (98)∆ | 38 (93)∆ |
| Ara h 8 sensitizationb | – | 132 (94) | 42 (70)# | ||||||
| Cor a 1 sensitizationb | – | 169 (94) | 35 (85) | ||||||
PH:1 not sensitized to peanut or hazelnut; PH::2 sensitized to peanut and/or Ara h8 and/or hazelnut and/or Cor a 1 but not to any of Ara h 1, 2, 3, Cor a 9, 14; PH::3 sensitized to peanut and/or Ara h8 and/or hazelnut and/or Cor a and to any of Ara h 1, 2, 3, Cor a 9, 14
P:1 not sensitized to peanut; P:2 sensitized to peanut but not to any of Ara h 1, 2, 3; P:3 sensitized to peanut and to any of Ara h 1, 2, 3
H:1 not sensitized to hazelnut; H:2 sensitized to hazelnut but not to any of Cor a 9, 14; H:3 sensitized to hazelnut and to any of Cor a 9, 14
aMean ± SD, bNumber (percentage), cGeometric Mean (95% CI), dmedian (IQR)
* p < 0.05 compared to group A1
#p < 0.05 compared to group A2
¤p < 0.05 compared to group B1
##p < 0.05 compared to group B2
∆p < 0.05 compared to group C1
☼p < 0.05 compared to group C2